{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:38:59Z","timestamp":1794472739871,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.039","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T11:31:12Z","timestamp":1483961472000},"page":"966-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA \u2013 Results of an international collaborative study"],"prefix":"10.1016","volume":"35","author":[{"given":"Sylvie","family":"Morgeaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ian","family":"Ragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Arabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Guinet-Morlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahjahan","family":"Shaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Volokhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Tordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Chapsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.039_b0005","series-title":"Laboratory techniques in rabies","first-page":"279e86","article-title":"The NIH test for potency","author":"Seligmann","year":"1973"},{"key":"10.1016\/j.vaccine.2016.12.039_b0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.12.039_b0015","unstructured":"The national toxicology program interagency center for the evaluation of alternative toxicological methods. Rabies vaccine workshop summary. http:\/\/ntp.niehs.nih.gov\/iccvam\/meetings\/rabiesvaccwksp-2011\/rabiesvaccinewkspsumm-30nov11.pdf."},{"key":"10.1016\/j.vaccine.2016.12.039_b0020","first-page":"37","article-title":"Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use","author":"Kr\u00e4mer","year":"2010","journal-title":"Pharmeur Bio Sci Notes"},{"key":"10.1016\/j.vaccine.2016.12.039_b0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biologicals.2013.08.003","article-title":"A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use","volume":"41","author":"Kr\u00e4mer","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.12.039_b0030","first-page":"183","article-title":"Use of the antibody assay in immunized mice for the determination of rabies vaccine potency","volume":"40","author":"Fitzgerald","year":"1978","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.12.039_b0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.110.1.269","article-title":"Antigenic properties of rabies virus components","volume":"110","author":"Wiktor","year":"1973","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.12.039_b0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0042-6822(91)90539-N","article-title":"Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein","volume":"185","author":"Whitt","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.12.039_b0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0042-6822(92)90465-2","article-title":"Rabies virus glycoprotein is a trimer","volume":"187","author":"Gaudin","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.12.039_b0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/viro.2002.1429","article-title":"Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers","volume":"297","author":"Roche","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.12.039_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0168-1702(02)00267-8","article-title":"Differential stability and fusion activity of Lyssavirus glycoprotein trimers","volume":"91","author":"Desm\u00e9zi\u00e8res","year":"2003","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2016.12.039_b0060","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1016\/j.vaccine.2014.06.058","article-title":"A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice","volume":"32","author":"Koraka","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.039_b0065","unstructured":"Rabies vaccine for human use prepared in cell cultures. Ph Eur Monogr 0216. 8th ed. Strasbourg (France): Council of Europe; 2015."},{"key":"10.1016\/j.vaccine.2016.12.039_b0070","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2013.10.019","article-title":"A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.039_b0075","first-page":"30","article-title":"The vaccines consistency approach project: an EPAA initiative","author":"Fabrizio","year":"2015","journal-title":"Pharmeur Bio Sci Notes"},{"key":"10.1016\/j.vaccine.2016.12.039_b0080","unstructured":"WHO expert committee on biological standardisation: report of the WHO collaborative study to calibrate a candidate replacement for the fifth international standard for rabies vaccine. http:\/\/apps.who.int\/iris\/bitstream\/10665\/70593\/1\/WHO_BS_08.2087_eng.pdf."},{"key":"10.1016\/j.vaccine.2016.12.039_b0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.039_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1045-1056(02)00070-2","article-title":"Inactivated rabies vaccine control and release: use of an ELISA method","volume":"31","author":"Fournier-Caruana","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.12.039_b0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI114260","article-title":"Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies","volume":"84","author":"Schumacher","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2016.12.039_b0100","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.12.039_b0105","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.81063-0","article-title":"Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor","volume":"86","author":"Sisso\u00ebff","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.12.039_b0110","series-title":"Etude structural et fonctionnelle du pseudog\u00e8ne rabique \u03c8: implications dans la r\u00e9plication et l\u2019\u00e9pid\u00e9miologie du virus de la rage.","author":"Veiga-Sacramento","year":"1991"},{"key":"10.1016\/j.vaccine.2016.12.039_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing antiglycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.12.039_b0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0042-6822(83)90349-5","article-title":"Chemical and immunological analysis of the rabies soluble glycoprotein","volume":"124","author":"Dietzschold","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.12.039_b0125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-1157(85)80042-1","article-title":"Use of monoclonal antibody for quantification of rabies vaccine glycoprotein by enzyme immunoassay","volume":"13","author":"Lafon","year":"1985","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2016.12.039_b0130","first-page":"429","article-title":"Three Rs approaches in the quality control of inactivated rabies vaccines","volume":"31","author":"Bruckner","year":"2003","journal-title":"ATLA"},{"key":"10.1016\/j.vaccine.2016.12.039_b0135","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2012.09.027","article-title":"Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults","volume":"30","author":"Gogtay","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.039_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antiviral Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:01:59Z","timestamp":1692622919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X16312646"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA \u2013 Results of an international collaborative study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}